Abstract:Recent breakthroughs in stem cell biology, especially the development of induced pluripotent stem cell technique, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in regenerative medicine. Improved understanding of stem cell biology, in addition to better control of stem cell fate, is critical to realize this potential. Small molecules, targeting specific signaling pathways and/or mechanisms, have been shown to be useful chemical tools in manipulating cell fate, state and function. These small molecules are starting to play increasingly important roles in both elucidating the fundamental biology of stem cells and facilitating the development of therapeutic approaches toward regenerative medicine. Such approaches could involve cell replacement therapies using homogenous functional cells produced under chemically defined conditions in vitro and the development of small-molecule drugs that can stimulate patients’ endogenous cells to repair and regenerate. Here, we review recent progress in using small molecules to sustain pluripotency, or induce differentiation of embryonic stem cells. We also highlight small molecules that can replace transcription factors and/or enhance efficiency during somatic cell reprogramming. Recent breakthroughs in stem cell biology, especially the development of induced pluripotent stem cell technique, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in regenerative medicine. Improved understanding of stem cell biology, in addition to better control of stem cell fate, is critical to realize this potential. Small molecules, targeting specific signaling pathways and/or mechanisms, have been shown to be useful chemical tools in manipulating cell fate, state and function. These small molecules are starting to play increasingly important roles in both elucidating the fundamental biology of stem cells and facilitating the development of therapeutic approaches toward regenerative medicine. Such approaches could involve cell replacement therapies using homogenous functional cells produced under chemically defined conditions in vitro and the development of small-molecule drugs that can stimulate patients’ endogenous cells to repair and regenerate. Here, we review recent progress in using small molecules to sustain pluripotency, or induce differentiation of embryonic stem cells. We also highlight small molecules that can replace transcription factors and/or enhance efficiency during somatic cell reprogramming. Having the ability to give rise to an entire functional organism. In mammals, the fertilized egg and early embryonic cells are totipotent. Totipotent cells not only have the potential to give rise to all the cell types of the body, but also the cell types of entire extraembryonic tissues. Having the potential to give rise to all of the cell types of the body, but not the cell types that make up the extraembryonic tissues such as the placenta. Embryonic stem cells derived from the inner cell mass of pre-implantation embryo are pluripotent. Pluripotent stem cells also include germline stem cells and derivatives, epiblast stem cells (EpiSCs) derived from the late epiblast layer of post-implantation embryos, and induced pluripotent stem (iPS) cells from somatic cells. Particularly, human embryonic stem cells (or mouse EpiSCs) can differentiate into trophoblast by BMP4 treatment. Whether it is a kind of artificial potential caused by in vitro conditions is still unknown. Having the ability to develop into different cell types within the same cell lineage. For example, hematopoietic stem cells that are multipotent can give rise to all the blood cell types. A pre-implantation embryo of about 150 cells produced by cleavage of the fertilized egg. The blastocyst is a hollow sphere made up of an outer layer of cells called trophoblast (forming the placenta eventually), a fluid-filled cavity, and a cluster of cells called inner cell mass. The cluster of cells attached to the wall of the blastocyst. These cells eventually give rise to all the organs and tissues of the whole organism, but do not give rise to the extraembryonic placenta tissues. The ICM cells are used to generate embryonic stem cells. The cell population in the post-implantation embryo that develops from the inner cell mass. The epiblast represents the final embryonic founder cells with the potential to give rise to all cell types of the adult body.

Molecular mechanisms underlying totipotency

Cell totipotency: molecular features, induction, and maintenance.

The regulation of totipotency transcription: Perspective from in vitro and in vivo totipotency

Epigenetic reprogramming in the transition from pluripotency to totipotency

Molecular Mechanisms of Pluripotency and Reprogramming

Hallmarks of Totipotent and Pluripotent Stem Cell States.

Evaluating totipotency using criteria of increasing stringency

Transition from totipotency to pluripotency in mice: insights into molecular mechanisms

Chromatin structure in totipotent mouse early preimplantation embryos

Myc and Dnmt1 impede the pluripotent to totipotent state transition in embryonic stem cells

Totipotency continuity from zygote to early blastomeres: a model under revision

The many faces of Pluripotency: in vitro adaptations of a continuum of in vivo states

Lessons from Expanded Potential of Embryonic Stem Cells: Moving Toward Totipotency

Totipotency of mouse zygotes extends to single blastomeres of embryos at the four-cell stage

Applications in gene editing in cell totipotency

Comparative Analyses of Single-Cell Transcriptomic Profiles between In Vitro Totipotent Blastomere-like Cells and In Vivo Early Mouse Embryonic Cells

Mechanism and Methods to Induce Pluripotency

Small Molecules That Modulate Embryonic Stem Cell Fate and Somatic Cell Reprogramming

Epigenetic regulation of reprogramming factors towards pluripotency in mouse preimplantation development

Induction of mouse totipotent stem cells by a defined chemical cocktail

Advance in Animal Cell Totipotency